KAICO

KAICO, a spin-off from Kyushu University, is a biotechnology company focused on the application of silkworms for the production of vaccines and pharmaceuticals. The company has developed a proprietary platform that utilizes silkworms to manufacture a variety of proteins, which serve as the active ingredients in their products. Their primary focus is on the development of oral vaccines for livestock, aiming to provide a more efficient and less stressful method of immunization for animals compared to traditional injectable vaccines.

The company's business model revolves around the research, development, and commercialization of these silkworm-produced vaccines and other protein-based products. KAICO collaborates with educational and research institutions to further advance their technology and product pipeline. The company is targeting the animal health market, with a specific emphasis on livestock, such as pigs. Their revenue is expected to be generated from the sale of their oral vaccines and other feed additives to farmers and agricultural businesses.

KAICO is also exploring the use of silkworm by-products for animal feed, indicating a broader strategy to utilize the full potential of their silkworm-based platform. The company has been successful in raising capital through series A funding rounds to support its research and development activities, as well as to conduct field trials for its products.

Keywords: biotechnology, animal health, oral vaccines, silkworm protein, livestock, pharmaceuticals, feed additives, agricultural technology, veterinary medicine, protein production